{"recordId":"st_bfud3pyecuctbpkc","canonicalUrl":"https://sotwire.com/stories/scipher-medicine-prismtcell-rheumatoid-arthritis-test-durham","jsonUrl":"https://sotwire.com/stories/scipher-medicine-prismtcell-rheumatoid-arthritis-test-durham/record","slug":"scipher-medicine-prismtcell-rheumatoid-arthritis-test-durham","headline":"Scipher Medicine adds PrismTcell to its rheumatoid arthritis tests","dek":"The Durham precision medicine company plans an early physician access program for the blood test in early 2027.","articleBody":"Scipher Medicine, a Durham immunology precision medicine company, announced on Oct. 28, 2026, the expected launch of an early physician access program for PrismTcell, a new blood-based test designed to predict which patients with rheumatoid arthritis will respond to abatacept, a T-cell activation inhibitor.\n\nPrismTcell joins PrismRA, Scipher's existing test for predicting non-response to TNF inhibitors, which the company says is the first and only molecular treatment response signature in immunology approved for reimbursement by CMS. According to the company, a clinical validation study found about a 2-fold higher ACR50 response rate to abatacept among patients selected by the PrismTcell signature than among patients without it. The test is performed in Scipher's CLIA-certified, CAP-accredited laboratory in North Carolina.\n\n\"We are excited to contribute to the future of precision diagnostics in immunology with the launch of PrismTcell, as we continue our mission to match the right treatments with the right patients,\" said Dr. Reg Seeto, chief executive officer of Scipher Medicine. The company also said it plans to enter precision therapeutics.\n\nScipher plans to start the PrismTcell Early Access Program in early Q1 2027, letting rheumatologists at participating practices order the test for adult patients being considered for abatacept. The development and validation data will be presented as a poster at ACR Convergence 2026, the American College of Rheumatology's annual meeting, on Nov. 10 in Orlando, Florida.","category":"launch","categoryLabel":"Launches","location":"Durham, NC","company":{"name":"Scipher Medicine","domain":"sciphermedicine.com"},"sample":false,"sampleDisclaimer":null,"publishedAt":"2026-10-28T13:45:38.854Z","updatedAt":"2026-10-28T13:45:38.854Z","badge":"Desk reported","trust":{"level":"desk_reported","doctrine":"Sotwire verifies who at the company stood behind the submission. It does not independently certify every underlying company claim as true.","verifies":"which named Sotwire editor wrote this from the cited sources","doesNotCertify":"independent truth of every claim","badge":"Desk reported","verificationMethod":"Named Sotwire editor, from the cited sources. Not a company attestation, and not an independent fact-check of every sentence.","domainChecked":false},"attestation":{"attested":false},"confirmation":null,"facts":[{"label":"Product","value":"PrismTcell, a blood-based molecular treatment response signature for abatacept"},{"label":"Condition","value":"Rheumatoid arthritis"},{"label":"Early access program","value":"Planned for early Q1 2027"},{"label":"Lab","value":"CLIA-certified, CAP-accredited laboratory in North Carolina"},{"label":"Existing test","value":"PrismRA"},{"label":"CEO","value":"Dr. Reg Seeto"},{"label":"Data presentation","value":"ACR Convergence 2026, Nov. 10, Orlando"}],"keyEvents":[{"date":"2026-10-28","label":"Scipher announced PrismTcell"},{"date":"2026-11-10","label":"PrismTcell poster at ACR Convergence 2026"}],"sources":[{"url":"https://www.globenewswire.com/news-release/2026/10/28/3390105/0/en/scipher-medicine-launches-prismtcell-the-next-molecular-treatment-response-signature-for-abatacept-in-rheumatoid-arthritis.html","title":"Scipher Medicine Launches PrismTcell, the Next Molecular Treatment Response Signature, for Abatacept in Rheumatoid Arthritis","publisher":"Scipher Medicine via GlobeNewswire"}],"source":{"url":"https://www.globenewswire.com/news-release/2026/10/28/3390105/0/en/scipher-medicine-launches-prismtcell-the-next-molecular-treatment-response-signature-for-abatacept-in-rheumatoid-arthritis.html","publisher":"Scipher Medicine","publishedAt":"2026-10-28T12:00:00.000Z"},"cover":{"url":"https://sotwire.com/covers/scipher-medicine-prismtcell-rheumatoid-arthritis-test-durham.webp","alt":"Scipher Medicine adds PrismTcell to its rheumatoid arthritis tests","provenance":"unknown","provenanceLabel":"Unknown origin","credit":null},"images":[],"provenanceMethod":"EXIF, XMP, and filename heuristic. Not C2PA cryptographic proof, and not a judgment that the depicted event is true.","provenanceDisclaimer":"v1 labels are heuristic (EXIF, XMP, filename), not cryptographic C2PA proof. Treat them as disclosure of observed metadata, not a guarantee that the image is genuine or that the depicted event is true.","citation":"Sotwire Desk, Scipher Medicine. \"Scipher Medicine adds PrismTcell to its rheumatoid arthritis tests.\" Sotwire, October 28, 2026, https://sotwire.com/stories/scipher-medicine-prismtcell-rheumatoid-arthritis-test-durham. Record ID: st_bfud3pyecuctbpkc. Desk reported.","sampleLabel":null,"correctionStatus":"No public corrections recorded","integrity":{"algorithm":"sha-256","hex":"2e16d76bb4947be226ade05d40172a0be663f9347aa0dcb5ee985642a8d14710","contentDigest":"sha-256=:LhbXa7SUe+ImreBdQBcqC+Zj+TR6oNy17phWQqjRRxA=:","scope":"Canonical JSON record excluding the integrity object"}}